Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
742.120USD
+3.400+0.46%
Close 10-07 16:00（ET）
77.80BMarket Cap
17.47P/E TTM
Regeneron Pharmaceuticals Inc (REGN) Stock Price Target & Forecast
Analyst Rating
Based on 30 analysts giving stock ratings to Regeneron Pharmaceuticals Inc in the past month.
Buy
6 Strong Buy
14 Buy
10 Hold
0 Sell
0 Strong Sell
Target Price
852.453USD+15.95%
REGN Analyst Recommendation Trends
In the current month, REGN has received 14 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the last month is 852.453.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
6
6
9
9
9
9
8
8
14
15
16
16
13
13
13
14
10
10
7
7
8
8
8
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
30
31
32
32
30
30
30
30
REGN Analyst Rating for Peer Comparison
Updated: Oct 6, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
8
16
12
1
0
37
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
18
3
1
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, REGN EPS is projected to reach 15.985 in FY2026Q3, following reported EPS of 12.616 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
10.62
8.94
10.26
15.99
16.33
Actual
8.19
6.99
12.62
--
--
Surprise
-22.83%
-21.76%
+22.93%
--
--
FAQs
What is Regeneron Pharmaceuticals Inc's expected revenue for the next quarter?
Regeneron Pharmaceuticals Inc's expected revenue is 4.54B.
What is Regeneron Pharmaceuticals Inc's price target?
Analysts forecast that Regeneron Pharmaceuticals Inc's price target is USD 855.82, with the highest forecast at USD 1.03K and the lowest forecast at USD 737.00.
How have Regeneron Pharmaceuticals IncREGN's recent earnings per share performed?
The market expectation was USD 12.62, while Regeneron Pharmaceuticals IncREGN's earnings per share (EPS) for the previous quarter was USD 6.99. EPS for the next quarter is expected at USD 15.99.
What is the analyst rating for Regeneron Pharmaceuticals Inc?
Based on the ratings of Regeneron Pharmaceuticals Inc's stock from 30 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.